OBJECTIVE: To look for profile of severe malaria and contribution of vivax infection to malarial morbidity in North Indian children. METHODS: Detailed clinical, biochemical and hematological characteristics of children hospitalized with severe malaria over last 3 y were recorded. Presence of malarial parasite on peripheral smear and/or positive antigen test was considered as diagnostic for malaria. RESULTS: A total of 131(55.3%) patients with Plasmodium vivax (Pv), 79 (33.3%) with Plasmodium falciparum (Pf) and 27 (11.4%) with mixed infections were admitted. Cerebral malaria, severe anemia and shock were significantly more frequently observed in Pf group, while hepatic, renal, respiratory, and bleeding complications were more commonly seen in Pv patients. Malaria mortality was highest in mixed infection (11.1%), followed by Pf (7.6%) and Pv (3%) group. CONCLUSIONS: Severe and fatal vivax malaria is an emerging recognized entity and challenges the perception of Pv as a benign disease. Further clinical studies and molecular research is required to understand emergence of severe malaria in vivax mono-infection.
OBJECTIVE: To look for profile of severe malaria and contribution of vivax infection to malarial morbidity in North Indian children. METHODS: Detailed clinical, biochemical and hematological characteristics of children hospitalized with severe malaria over last 3 y were recorded. Presence of malarial parasite on peripheral smear and/or positive antigen test was considered as diagnostic for malaria. RESULTS: A total of 131(55.3%) patients with Plasmodium vivax (Pv), 79 (33.3%) with Plasmodium falciparum (Pf) and 27 (11.4%) with mixed infections were admitted. Cerebral malaria, severe anemia and shock were significantly more frequently observed in Pf group, while hepatic, renal, respiratory, and bleeding complications were more commonly seen in Pv patients. Malaria mortality was highest in mixed infection (11.1%), followed by Pf (7.6%) and Pv (3%) group. CONCLUSIONS: Severe and fatal vivax malaria is an emerging recognized entity and challenges the perception of Pv as a benign disease. Further clinical studies and molecular research is required to understand emergence of severe malaria in vivax mono-infection.
Authors: S Yamaguchi; T Kubota; T Yamagishi; K Okamoto; T Izumi; M Takada; S Kanou; M Suzuki; J Tsuchiya; T Naruse Journal: Am J Hematol Date: 1997-11 Impact factor: 10.047
Authors: S Looareesuwan; J G Davis; D L Allen; S H Lee; D Bunnag; N J White Journal: Southeast Asian J Trop Med Public Health Date: 1992-03 Impact factor: 0.267
Authors: Fernando Val; Kim Machado; Lisiane Barbosa; Jorge Luis Salinas; André Machado Siqueira; Maria Graças Costa Alecrim; Hernando Del Portillo; Quique Bassat; Wuelton Marcelo Monteiro; Marcus Vinícius Guimarães Lacerda Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: Spinello Antinori; Alberto Corona; Anna Lisa Ridolfo; Laura Galimberti; Davide Ricaboni; Laura Milazzo; Mario Corbellino Journal: Malar J Date: 2016-02-19 Impact factor: 2.979
Authors: Evelyn K P Riccio; Paulo R R Totino; Lilian R Pratt-Riccio; Vitor Ennes-Vidal; Irene S Soares; Maurício Martins Rodrigues; José Maria de Souza; Cláudio Tadeu Daniel-Ribeiro; Maria de Fátima Ferreira-da-Cruz Journal: Malar J Date: 2013-09-16 Impact factor: 2.979